Search
Dexamethasone Treatment Options
A collection of 1463 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
661 - 672 of 1463
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Completed
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be compared to another medicine called pomalidomide, given with dexamethasone with people with the same condition. Relapsed means the previous cancer treatment stopped working, over time. Refractory means they did not respond to previous cancer treatment. Another aim is to check for side effects from the study medicines.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2022
Locations: Highlands Oncology Group, Fayetteville, Arkansas +110 locations
Conditions: Relapsed and/or Refractory Multiple Myeloma
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Completed
This study will evaluate melflufen in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma in whose disease is refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2022
Locations: Innovative Clinical Research Institute (ICRI), Whittier, California +19 locations
Conditions: Multiple Myeloma
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Withdrawn
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2022
Locations: Weill Cornell Medicine - Multiple Myeloma Center, New York, New York
Conditions: Amyloid, Amyloidosis, AL Amyloidosis
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Completed
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Providence St. Joseph Medical Center, Burbank, California +240 locations
Conditions: Multiple Myeloma
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
Terminated
The primary objectives of this study included the following:
Phase 1b:
* To establish the maximum tolerated dose (MTD) of oprozomib given in combination with lenalidomide and dexamethasone (ORd) or with cyclophosphamide and dexamethasone (OCyd)
* To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide
Phase 2:
* To estimate the antitumor activity of each combination regimen, as measured by overall response... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2022
Locations: Clearview Cancer Institute, Huntsville, Alabama +13 locations
Conditions: Multiple Myeloma
Palliative Management of Inoperable Malignant Bowel Obstruction
Terminated
To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Malignant Bowel Obstruction
Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery
Terminated
To monitor intraocular pressure in glaucoma patients after cataract surgery preformed in conjunction with minimally invasive glaucoma surgery (MIGS)
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
11/08/2022
Locations: The Eye Associates of Manatee, Bradenton, Florida
Conditions: Cataract
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Terminated
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival \[EFS\]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/07/2022
Locations: Not set, Los Angeles, California +76 locations
Conditions: Lymphoma, Non-Hodgkin
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Terminated
This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as dexamethasone, filgrastim, pegfilgrastim, cyclophosphamide, methotrexate, cytarabine and vincristine sulfate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Completed
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Colorado Blood Cancer Institute, Denver, Colorado +8 locations
Conditions: Multiple Myeloma, Renal Impairment
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Completed
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant.
Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2022
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
Unknown
The main aim of the pilot study is to determine preliminary estimates of the safety, tolerability, and comfort of a dexamethasone-eluting therapeutic contact lens drug delivery system (TCL-DDS) for the treatment of recurrent cystoid macular edema. Secondarily, feasibility of the TCL-DDS system will be investigated.
1. Safety: To establish that a topical dexamethasone delivery system has an acceptable safety profile by determining the incidence and severity of ocular adverse events, as identifie... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/27/2022
Locations: MEEI, Boston, Massachusetts
Conditions: Cystoid Macular Edema
661 - 672 of 1463